Latest news
Categories
News archive
Interview with CEO Andreas Bhagwani on first large-scale delivery
18 October, 2023
Nanologica’s CEO Andreas Bhagwani interviewed by Redeye analyst Filip Einarsson regarding Nanologica’s first large-scale delivery to an insulin manufacturer for evaluation in production and what this means for the company going forward. Watch the video here (in Swedish).
Nanologica Delivers Silica to Insulin Manufacturer
17 October, 2023
Nanologica delivers silica to an insulin manufacturer in Asia against an order received last year. The delivery consists of silica for evaluation in full-scale production. The delivery is made against an order that was placed last year and Nanologica will provide the silica free of charge in return for being provided with results and insights into the final evaluation. The customer, which is one of the world’s largest insulin manufacturers, finances all other costs for
CEO Andreas Bhagwani is interviewed at Redeye after the release of the interim report Q2 2023
8 July, 2023
Intervju med vd Andreas Bhagwani gällande delårsrapporten för Q2 2023.
Interim Report Q2 2023 Nanologica AB (publ)
7 July, 2023
FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK